Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

Presentation THT 2025

GSN Ablation Reduces Estimated Stressed Blood Volume in HFpEF: Supports REBALANCE-HF Mechanism of Action

Presenter: Marat Fudim

February 13, 2025

Presentation THT 2025

Win Ratio Analysis of Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: REBALANCE-HF Randomized Trial

Presenter: Marat Fudim

February 12, 2025

Presentation THT 2024

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: REBALANCE-HF Randomized Trial 12-Month Results

Presenter: Sanjiv J. Shah

March 05, 2024

Presentation THT 2024

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: Differences in Medication Changes in in the Sham and Treatment groups of REBALANCE-HF

Presenter: Sheldon E. Litwin

March 04, 2024

Presentation THT 2024

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: REBALANCE-HF Stress Blood Volume Analysis

Presenter: Marat Fudim

March 04, 2024

News Conference News THT 2023

Preliminary Results Suggest Benefit of Splanchnic Nerve Ablation in HFpEF

Todd Neale

March 22, 2023

Presentation THT 2023

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: Updated Results of the REBALANCE-HF Trial Roll-in Cohort

Presenter: Marat Fudim

March 21, 2023

Presentation THT 2023

Update on the Phase 2 REBALANCE-HF Trial of SAVM for HFpEF/HFmrEF: Lessons Learned and Future Directions

Presenter: Sanjiv Shah

March 21, 2023

Presentation THT 2022

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Presenter: Sanjiv Shah

February 01, 2022

Advertisement

GSN Ablation Reduces Estimated Stressed Blood Volume in HFpEF: Supports REBALANCE-HF Mechanism of Action

Win Ratio Analysis of Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: REBALANCE-HF Randomized Trial

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: REBALANCE-HF Randomized Trial 12-Month Results

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: Differences in Medication Changes in in the Sham and Treatment groups of REBALANCE-HF

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: REBALANCE-HF Stress Blood Volume Analysis

Preliminary Results Suggest Benefit of Splanchnic Nerve Ablation in HFpEF

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: Updated Results of the REBALANCE-HF Trial Roll-in Cohort

Update on the Phase 2 REBALANCE-HF Trial of SAVM for HFpEF/HFmrEF: Lessons Learned and Future Directions

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content